


# PRODUCT INFORMATION



## Dapiglutide (sodium salt)

Item No. 41259

**Formal Name:** L-histidyl-2-methylalanyl-L- $\alpha$ -glutamylglycyl-L-seryl-L-phenylalanyl-L-threonyl-L-seryl-L- $\alpha$ -glutamyl-L-leucyl-L-alanyl-L-threonyl-L-isooleucyl-L-leucyl-L- $\alpha$ -aspartyl-N<sup>6</sup>-[N-(17-carboxy-1-oxoheptadecyl)-L- $\gamma$ -glutamyl]-L-lysyl-L-glutamyl-L-alanyl-L-alanyl-L-arginyl-L- $\alpha$ -aspartyl-L-phenylalanyl-L-isooleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-isooleucyl-L-glutamyl-L-histidyl-L-lysyl-L-isooleucyl-L-threonyl-L-aspartic acid



**MF:** C<sub>192</sub>H<sub>302</sub>N<sub>46</sub>O<sub>57</sub> • XNa

**FW:** 4,166.8

**Purity:** ≥98%

**Supplied as:** A solid

**Storage:** -20°C

**Stability:** ≥4years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Dapiglutide (sodium salt) is supplied as a solid. Aqueous solutions of dapiglutide (sodium salt) can be prepared by directly dissolving the solid in aqueous buffers. Dapiglutide (sodium salt) is slightly (0.1-1 mg/ml) soluble in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

### Description

Dapiglutide is a dual glucagon-like peptide 1 receptor (GLP-1R) and GLP-2R agonist.<sup>1</sup> It induces cAMP accumulation in HEK293 cells expressing human GLP-1R or GLP-2R (EC<sub>50</sub>s = 190 and 210 pM, respectively). Dapiglutide (6 nmol/kg) reduces peak blood glucose levels in an oral glucose tolerance test and increases intestinal wet weight in mice. It decreases gastric emptying and increases intestinal weight and length in rats (ED<sub>50</sub>s = 7.6, 20.7, and 10.7 nmol/kg, respectively). Dapiglutide also promotes body weight recovery, decreases stool water content, and increases intestinal villus height and intestinal length in a mouse model of short bowel and intestinal insufficiency induced by 40% ileocecal resection.

### Reference

1. Reiner, J., Berlin, P., Held, J., *et al.* Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. *JPEN J. Parenter. Enteral Nutr.* **46(5)**, 1107-1118 (2022).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/23/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)